Year None202420232022202120202019201820172016 Date Latest Press Release December 12, 2016 Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) November 29, 2016 Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) November 21, 2016 Eiger BioPharmaceuticals to Participate in Two Investor Conferences in November 2016 November 14, 2016 Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting November 14, 2016 Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program November 8, 2016 Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results October 24, 2016 Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection October 19, 2016 Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection October 17, 2016 Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA) October 13, 2016 Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting Pagination First page « first Previous page ‹ previous … Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Current page 22 Page 23 Page 24 Next page next › Last page last »